Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Steven R LentzDragana JanicKaan KavakliPredrag MiljicJohannes Oldenburg Margareth Castro OzeloElena SantagostinoTakashi SuzukiSilva Zupancic ŠalekLars KorsholmIrina MatytsinaAndreas Tiede

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

Extended use of turoctocog alfa is safe and effective for prevention and treatment of bleeding episodes in previously treated patients with haemophilia A across all ages.

Keyphrases

replacement therapy
atrial fibrillation
study protocol
phase iii
smoking cessation
open label
placebo controlled